Puma Biotech (PBYI) Tops Q4 EPS by 95c, Beat on Revenues

Note: EPS may not be comparable

Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of ($1.03), $0.95 better than the analyst estimate of ($1.98). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $20.01 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Robinhood prices $2B convertible notes offering due 2029
• AeroVironment restates quarterly financials, citing $89M goodwill error